Table 1.

Clinicopathologic information and corresponding fluorescence in situ hybridization analysis of both autopsy and surgical cohorts.

Case	Age at Diagnosis	Primary tumor type and grade	Stage at Diagnosis	Age at Death	Molecular Subtype	PBC c-myc	MBC c-myc
1	54	ILC, Grade 2	T2N0M0	65	LA LOSS	NDA	NDA
2	59	IDC, Grade 2	T1N0M0	68	LA	NDA	NDA
3	48	IDC, Grade 3	T2N3M0	54	LA	NDA	NDA
4	71	IDC, Grade 3	T2N0MX	79	BLC	NDA	NDA
5	35	IDC, Grade 3	T2N1MX	36	HER2 LOSS	NDA	NDA
6	57	IDC, Grade 2	T4N1M1	58	LA LOSS	NDA	NDA
7	33	IDC, Grade 3	T3N1M0	37	BLC	DUP	DUP
8	38	IDC, Grade 3	T2NXMX	43	LA	DUP	DUP
9	42	IDC, Grade 3	T3N1M1	47	HER2	NDA	AMP
10	51	IDC, Grade 3	T2N0M0	53	BLC	DUP	AMP
11	28	IDC, Grade 3	T2N1MX	38	LA	DUP	AMP
12	33	IDC, Grade 3	T1N1MX	37	BLC	DUP	AMP
13	56	IDC, Grade 2	T2N1M0	61	LA LOSS	AMP	AMP
14	40	IDC, Grade 3	T1N1M0	48	LA LOSS	AMP	AMP
15	47	IDC, Grade 3	T2N1MX	48	BLC	AMP	AMP
16	33	IDC, Grade 3	T3N1M1	Still alive	HER2	NDA	NDA
17	50	IDC, Grade 3	T2N1MX	Still alive	LA	NDA	NDA
18	34	IDC, Grade 3	T2N2M1	35	BLC	DUP	AMP
19	38	ILC, Grade not reported	T1cN0MX	44	LA	NDA	NDA
20	45	IDC, Grade not reported	Unknown	Still alive	LA	NDA	AMP
21	36	IDC, Grade 2	T1cN0MX	Still alive	HER2	Failed	AMP
99	39	IDC, Grade 3	T2N0MX	45	BLC	NDA	DUP
23	53	IDC, Grade not reported	Unknown	55	BLC	AMP	AMP
24	38	IDC, Grade 3	T1cN0MX	43	BLC	NDA	NDA
25	53	IDC, Grade 3	T2N2MX	59	LA	NDA	NDA

Abbreviations: BLC, Basal-like carcinoma; HER2, HER2 amplified; HER2 LOSS, HER2 loss in metastases; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LA, Luminal A; LA LOSS, Luminal A, ER/PR loss in metastases; MBC, metastatic breast cancer; NDA, No duplication or amplification PBC, primary breast cancer